TECH
Bio-Techne
$55.61
▼ 4.0%Updated Today 7:15 PM ET
▲ Up 15.6% over the last 12 months
Market Cap
$9.07B
P/E
83.6x
Forward P/E (est.)
99.4x
ROE
5.4%
Revenue Growth
0.2%
EPS Growth
-15.9%
Profit Margin
9.0%
FCF Yield
3.9%
Debt / Equity
0.18x
ROIC
4.0%
Interest Coverage
9.12x
Current Ratio
4.49x
Dividend Yield
0.6%
Implied Growth (rev. DCF)
6.0%
Rating Score
29/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what TECH's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. TECH trades near $55.61, around its 50-day average ($52.43) and 200-day average ($57.46). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 63 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. TECH's is $1.97 (~3.5% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month TECH found buyers near $44.27 (support) and sellers near $57.33 (resistance); its 52-week range is $43.20–$72.16. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Bio-Techne (TECH) is a mid-cap company in the Life Sciences Tools & Services industry, part of the Health Care sector of the S&P 500, with a market value around $9.07B.
In its latest reported year it generated about $1.22B in revenue and $73.40M in net profit.
Our model rates TECH Weak (29/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
7.0%
Revenue moved from $931.03M in 2021 to $1.22B in 2025, a 7.0% compound annual growth rate. The most recent year was roughly flat (0.2%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
64.8%
Operating Margin
8.4%
Net Margin
6.0%
ROE
5.4%
Bio-Techne keeps about 9.0% of each sales dollar as net profit, with a 64.8% gross margin and 8.4% operating margin. Return on equity is 5.4% and return on invested capital about 4.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$12.50M
Net Debt
-$197.32M
Net cash position
Net Debt / EBITDA
-1.93x
Debt / Equity
0.18x
Leverage: debt-to-equity is 0.2x, and operating profit covers interest about 9.1x, with a current ratio of 4.5x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $12.50M of total debt against $209.82M of cash.
Operating CF
$287.56M
Free Cash Flow
$256.55M
FCF Margin
21.0%
In the latest year Bio-Techne produced about $287.56M of operating cash flow and $256.55M of free cash flow after capital spending. That is a free-cash-flow yield of about 3.9% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
83.6x
P/S
7.19x
P/B
4.35x
EV / EBITDA
40.36x
TECH trades at 83.6x trailing earnings (about 99.4x on estimated forward earnings), 7.2x sales, and 4.3x book value. Reverse-engineering today's price implies the market expects roughly 6.0% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How TECH stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), TECH ranks #56 of 59 by our overall rating. It trades at a premium versus the sector on earnings (83.6x P/E vs. 25.4x median) with a lower return on equity (5.4% vs. 14.9%) and slower revenue growth (0.2% vs. 7.9%).
P/E vs sector
83.6x
median 25.4x
ROE vs sector
5.4%
median 14.9%
Growth vs sector
0.2%
median 7.9%
Sector rank
#56
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$27.09 – $45.51
vs. $55.61 today · expected CAGR -13% – -4%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $1.26B | $1.29B | $1.33B | $1.37B | $1.41B |
| Net income | $75.37M | $77.63M | $79.96M | $82.36M | $84.83M |
| EPS | $0.48 | $0.50 | $0.51 | $0.53 | $0.54 |
| Share price (low) | $24.07 | $24.79 | $25.54 | $26.30 | $27.09 |
| Share price (high) | $40.44 | $41.65 | $42.90 | $44.19 | $45.51 |
| CAGR (low–high) | -57% / -27% | -33% / -13% | -23% / -8% | -17% / -6% | -13% / -4% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for TECH:
- A conservative balance sheet (debt/equity 0.2x) lowers risk.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against TECH:
- Revenue growth is slow (0.2%), limiting the upside engine.
- A rich 83.6x earnings multiple prices in a lot of growth.
- Our model's overall read is Weak (29/100).
Valuation risk — at 83.6x earnings, disappointing results could compress the multiple.
Growth risk — sluggish revenue (0.2%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Bio-Techne is a mid-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 83.6x earnings, which our model scores Weak (29/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.